David Liebowitz

2.9k total citations · 1 hit paper
22 papers, 2.3k citations indexed

About

David Liebowitz is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, David Liebowitz has authored 22 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 6 papers in Immunology. Recurrent topics in David Liebowitz's work include Viral-associated cancers and disorders (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and CAR-T cell therapy research (5 papers). David Liebowitz is often cited by papers focused on Viral-associated cancers and disorders (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and CAR-T cell therapy research (5 papers). David Liebowitz collaborates with scholars based in United States, France and Australia. David Liebowitz's co-authors include Elliott Kieff, David Wang, Everett E. Vokes, Ralph R. Weichselbaum, Sean N. Tucker, Shaily Garg, Walter M. Stadler, Robert J. Amato, Jeffery A. Sosman and Nicholas J. Vogelzang and has published in prestigious journals such as New England Journal of Medicine, Cell and The Lancet.

In The Last Decade

David Liebowitz

20 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells

1985 1.1k citations David Wang, David Liebowitz et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Liebowitz United States	16	1.6k	751	533	479	387	22	2.3k
Joyce D. Fingeroth United States	26	1.8k 1.1×	661 0.9×	501 0.9×	1.2k 2.4×	473 1.2×	45	3.1k
Ingemar Ernberg Sweden	18	1.0k 0.6×	485 0.6×	521 1.0×	426 0.9×	990 2.6×	22	2.3k
Debbie Croom-Carter United Kingdom	24	2.5k 1.6×	1.4k 1.9×	561 1.1×	1.1k 2.3×	412 1.1×	26	3.2k
Claire Shannon‐Lowe United Kingdom	27	1.7k 1.0×	791 1.1×	272 0.5×	830 1.7×	348 0.9×	36	2.3k
J. Alero Thomas United Kingdom	29	1.1k 0.7×	598 0.8×	284 0.5×	1.2k 2.5×	440 1.1×	57	3.0k
Toyoro Õsato Japan	23	2.0k 1.3×	1.2k 1.6×	543 1.0×	740 1.5×	330 0.9×	100	2.7k
F Sigaux France	28	2.2k 1.4×	953 1.3×	599 1.1×	876 1.8×	666 1.7×	69	4.0k
Rachel Hood Edwards United States	19	1.7k 1.1×	762 1.0×	465 0.9×	443 0.9×	944 2.4×	24	2.5k
Caroline Alfieri Canada	21	1.5k 0.9×	675 0.9×	585 1.1×	493 1.0×	190 0.5×	38	2.0k
Jerome E. Tanner Canada	19	944 0.6×	381 0.5×	374 0.7×	581 1.2×	262 0.7×	34	1.7k

Countries citing papers authored by David Liebowitz

Since Specialization

Citations

This map shows the geographic impact of David Liebowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Liebowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Liebowitz more than expected).

Fields of papers citing papers by David Liebowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Liebowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Liebowitz. The network helps show where David Liebowitz may publish in the future.

Co-authorship network of co-authors of David Liebowitz

This figure shows the co-authorship network connecting the top 25 collaborators of David Liebowitz. A scholar is included among the top collaborators of David Liebowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Liebowitz. David Liebowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Akce, Mehmet, Siwen Hu‐Lieskovan, Matthew J. Reilley, et al.. (2022). A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).. Journal of Clinical Oncology. 40(16_suppl). 2604–2604. 8 indexed citations

Patel, Krish, Jean‐Marie Michot, Asher Chanan‐Khan, et al.. (2021). Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 138(Supplement 1). 2494–2494. 19 indexed citations

McIlwain, David R., Han Chen, Sizun Jiang, et al.. (2021). Human influenza virus challenge identifies cellular correlates of protection for oral vaccination. Cell Host & Microbe. 29(12). 1828–1837.e5. 23 indexed citations

Liebowitz, David, et al.. (2021). Can pre-trained Transformers be used in detecting complex sensitive sentences? - A Monsanto case study. 90–97. 5 indexed citations

Liebowitz, David, Keith Gottlieb, Nikita Kolhatkar, et al.. (2020). Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. The Lancet Infectious Diseases. 20(4). 435–444. 87 indexed citations

Patel, Krish, Jean‐Marie Michot, Asher Chanan‐Khan, et al.. (2019). Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Blood. 134(Supplement_1). 4079–4079. 24 indexed citations

Kim, Leesun, David Liebowitz, Marcela F. Pasetti, et al.. (2018). Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight. 3(13). 100 indexed citations

Liebowitz, David, et al.. (2015). High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. The Lancet Infectious Diseases. 15(9). 1041–1048. 66 indexed citations

Giannola, Diane, Warren D. Shlomchik, M Jegathesan, et al.. (2000). Hematopoietic Expression of Hoxb4 Is Regulated in Normal and Leukemic Stem Cells through Transcriptional Activation of the Hoxb4 Promoter by Upstream Stimulating Factor (Usf)-1 and Usf-2. The Journal of Experimental Medicine. 192(10). 1479–1490. 40 indexed citations

10.

Stadler, Walter M., Nicholas J. Vogelzang, Robert J. Amato, et al.. (2000). Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study. Journal of Clinical Oncology. 18(2). 371–371. 167 indexed citations

11.

Liebowitz, David, et al.. (1999). In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemotherapy and Pharmacology. 44(1). 81–87. 46 indexed citations

12.

Stoffel, Archontoula, Diane C. Louie, Kenneth Krauter, et al.. (1999). Chromosome 18 breakpoint in t(11;18)(q21;q21) translocation associated with MALT lymphoma is proximal to BCL2 and distal to DCC. Genes Chromosomes and Cancer. 24(2). 156–159.

13.

Stoffel, Archontoula, Diane C. Louie, Kenneth Krauter, et al.. (1999). Chromosome 18 breakpoint in t(11;18)(q21;q21) translocation associated with MALT lymphoma is proximal toBCL2 and distal toDCC. Genes Chromosomes and Cancer. 24(2). 156–159. 25 indexed citations

14.

Liebowitz, David. (1998). Epstein–Barr Virus and a Cellular Signaling Pathway in Lymphomas from Immunosuppressed Patients. New England Journal of Medicine. 338(20). 1413–1421. 179 indexed citations

15.

Liebowitz, David, Kelvin P. Lee, & C H June. (1998). Costimulatory approaches to adoptive immunotherapy. Current Opinion in Oncology. 10(6). 533–541. 43 indexed citations

16.

Vokes, Everett E., David Liebowitz, & Ralph R. Weichselbaum. (1997). Nasopharyngeal carcinoma. The Lancet. 350(9084). 1087–1091. 196 indexed citations

17.

Kieff, Elliott & David Liebowitz. (1989). 10 Oncogenesis by Herpesviruses. Cold Spring Harbor Monograph Archive. 18. 259–280.

18.

Arlin, Zalmen A., et al.. (1989). Philadelphia Chromosome (Ph<sup>1</sup>-Positive Acute Lymphoblastic Leukemia (ALL) Is Resistant to Effective Therapy for Ph<sup>1</sup> Negative ALL. Acta Haematologica. 81(4). 217–218. 2 indexed citations

19.

Liebowitz, David, Raphael Kopan, Elaine Fuchs, Jeffery T. Sample, & Elliott Kieff. (1987). An Epstein-Barr Virus Transforming Protein Associates with Vimentin in Lymphocytes. Molecular and Cellular Biology. 7(7). 2299–2308. 46 indexed citations

20.

Wang, David, David Liebowitz, & Elliott Kieff. (1985). An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 43(3). 831–840. 1060 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact